|
1
|
Xin Y, Yin F, Qi S, Shen L, Xu Y, Luo L,
Lan L and Yin Z: Parthenolide reverses doxorubicin resistance in
human lung carcinoma A549 cells by attenuating NF-κB activation and
HSP70 up-regulation. Toxicol Lett. 221:73–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen SY, Zheng XW, Cai JX, Zhang WP, You
HS, Xing JF and Dong YL: Histone deacetylase inhibitor reverses
multidrug resistance by attenuating the nucleophosmin level through
PI3K/Akt pathway in breast cancer. Int J Oncol. 49:294–304.
2016.PubMed/NCBI
|
|
3
|
Gillet JP and Gottesman MM: Mechanisms of
multidrug resistance in cancer. Methods Mol Biol. 596:47–76. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu Y, Li CS and Dong Q: Chinese herb
related molecules of cancer-cell-apoptosis: A minireview of
progress between Kanglaite injection and related genes. J Exp Clin
Cancer Res. 27:312008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu F, Gao J, Zeng Y and Liu CX: Inhibition
of Coix seed extract on fatty acid synthase, a novel target for
anticancer activity. J Ethnopharmacol. 119:252–258. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo
N, Li XK and Tang W: Chinese herbal medicines as adjuvant treatment
during chemo- or radio-therapy for cancer. Biosci Trends.
4:297–307. 2010.PubMed/NCBI
|
|
7
|
Zhu L, Yang Z, Wang S and Tang Y:
Kanglaite for treating advanced non-small-cell lung cancer: A
systematic review. Zhongguo Fei Ai Za Zhi. 12:208–215. 2009.(In
Chinese). PubMed/NCBI
|
|
8
|
Li DP: General survey and progress in
clinical trials abroad over Kanglaite injection. Chin J Integr Med.
10:233–235. 2004. View Article : Google Scholar
|
|
9
|
Wang JC, Tian JH, Ge L, Gan YH and Yang
KH: Which is the best Chinese herb injection based on the FOLFOX
regimen for gastric cancer? A network meta- analysis of randomized
controlled trials. Asian Pac J Cancer Prev. 15:4795–4800. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhan YP, Huang XE, Cao J, Lu YY, Wu XY,
Liu J, Xu X, Xiang J and Ye LH: Clinical safety and efficacy of
Kanglaite® (Coix Seed Oil) injection combined with chemotherapy in
treating patients with gastric cancer. Asian Pac J Cancer Prev.
13:5319–5321. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Beck-Engeser GB, Lum AM, Huppi K, Caplen
NJ, Wang BB and Wabl M: Pvt1-encoded microRNAs in oncogenesis.
Retrovirology. 5:42008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guan Y, Kuo WL, Stilwell JL, Takano H,
Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, et al:
Amplification of PVT1 contributes to the pathophysiology of ovarian
and breast cancer. Clin Cancer Res. 13:5745–5755. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takahashi Y, Sawada G, Kurashige J, Uchi
R, Matsumura T, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, et
al: Amplification of PVT-1 is involved in poor prognosis via
apoptosis inhibition in colorectal cancers. Br J Cancer.
110:164–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ding J, Li D, Gong M, Wang J, Huang X, Wu
T and Wang C: Expression and clinical significance of long
non-coding RNA-PVT1 in human gastric cancer. Onco Targets Ther.
7:1625–1630. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu E, Liu Z, Zhou Y, Mi R and Wang D:
Overexpression of long non-coding RNA PVT1 in ovarian cancer cells
promotes cisplatin resistance by regulating apoptotic pathways. Int
J Clin Exp Med. 8:20565–20572. 2015.PubMed/NCBI
|
|
16
|
Zhang XW, Bu P, Liu L, Zhang XZ and Li J:
Overexpression of long non-coding RNA PVT1 in gastric cancer cells
promotes the development of multidrug resistance. Biochem Biophys
Res Commun. 462:227–232. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang
Z and Han J: The advantages of using traditional Chinese medicine
as an adjunctive therapy in the whole course of cancer treatment
instead of only terminal stage of cancer. Biosci Trends. 9:16–34.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pin-Tian L, Kun Z, Ya-zhen W and Bin L:
Effect of Kanglaite Injection associated with Cisplatin in lung
adno carcinoma cells A549. Chin Traditional Patent Med. 33:393–396.
2011.
|
|
19
|
Minchinton AI and Tannock IF: Drug
penetration in solid tumours. Nat Rev Cancer. 6:583–592. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cole SP: Targeting multidrug resistance
protein 1 (MRP1, ABCC1): Past, present, and future. Annu Rev
Pharmacol Toxicol. 54:95–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cui D, Yu CH, Liu M, Xia QQ, Zhang YF and
Jiang WL: Long non-coding RNA PVT1 as a novel biomarker for
diagnosis and prognosis of non-small cell lung cancer. Tumor Biol.
37:4127–4134. 2016. View Article : Google Scholar
|
|
22
|
Ding C, Yang Z, Lv ZDUC, Xiao H, Peng C,
Cheng S, Xie H, Zhou L, Wu J and Zheng S: Long non-coding RNA PVT1
is associated with tumor progression and predicts recurrence in
hepatocellular carcinoma patients. Oncol Lett. 9:955–963.
2015.PubMed/NCBI
|
|
23
|
Zhou Q, Chen J, Feng J and Wang J: Long
noncoding RNA PVT1 modulates thyroid cancer cell proliferation by
recruiting EZH2 and regulating thyroid-stimulating hormone receptor
(TSHR). Tumour Biol. 37:3105–3113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Riquelme E, Suraokar MB, Rodriguez J, Mino
B, Lin HY, Rice DC, Tsao A and Wistuba II: Frequent coamplification
and cooperation between C-MYC and PVT1 oncogenes promote malignant
pleural mesothelioma. J Thorac Oncol. 9:998–1007. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
You L, Chang D, Du HZ and Zhao YP:
Genome-wide screen identifies PVT1 as a regulator of Gemcitabine
sensitivity in human pancreatic cancer cells. Biochem Biophys Res
Commun. 407:1–6. 2011. View Article : Google Scholar : PubMed/NCBI
|
